Iambic Therapeutics develops AI-driven platforms for drug discovery, focusing on optimizing medicines for specific disease profiles and addressing unmet patient needs. The company self-describes its approach as innovative and efficient.

Iambic Therapeutics

Iambic Therapeutics is disrupting the therapeutics landscape with its unique AI-driven drug-discovery platform. Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters with strong track records of success in delivering clinically validated therapeutics. The Iambic platform has been demonstrated to deliver high-quality, differentiated therapeutics to clinic with unprecedented speed and across multiple target classes and mechanisms of action. The Iambic team is advancing an internal pipeline of clinical assets to address urgent unmet patient needs. Learn more about the Iambic team, platform, and pipeline at iambic.ai.

Join Sayan Mondal, Iambic Therapeutics Executive Director of Computational Chemistry and Co-Chair of the PDDP Summit, in a panel discussion on pioneering the biopharma landscape with Al-driven drug discovery and development. Precision Evolution Global

Date/time: October 13th, 12:10pm - 1:15pm PT

#drugdiscovery #artificialintelligence #machinelearning

Tune into Iambic co-founder and CEO Thomas Miller discussing the genesis and future of Iambic on BIOS!

Iambic Therapeutics (formerly known as Entos) announced the closing of its oversubscribed $100 million Series B financing round to advance AI-discovered therapeutics into clinical development. Concurrently, Iambic has entered a collaboration with NVIDIA to leverage NVIDIA technology to accelerate drug discovery. 

Said CEO Thomas Miller, “At Iambic, our world-class team has combined physics and AI to create a differentiated drug discovery platform that achieves a step-change in the speed and success rate for delivering best-in-class and first-in-class development candidates to clinic.” 

The funding will be used to advance multiple candidates into clinical development (including a selective brain-penetrant HER2 inhibitor and a selective dual CDK2/4 inhibitor), expand its pipeline with additional candidates, and build next-generation AI and automation technologies for drug discovery. 

The new name of Iambic Therapeutics reflects its transition to a company with the additional capability of clinical development of candidates identified through its AI-driven discovery platform.  

We’re proud to support this innovative company and welcome Iambic Therapeutics to the Illumina Ventures portfolio.  

Read the full press release: https://lnkd.in/ex3JkGZY

Ascenta Capital 
Abingworth 
NVIDIA
Gradiant Corporation 
Nexus Venture Partners
Catalio Capital Management 
Coatue 
Freeflow Ventures
OrbiMed 
Sequoia Capital

Ron Mazumder 
Charles Lin
Bill Rastetter

HomeLab™ at UC San Diego

#PartnerNews #MachineLearning #AI #ArtificalIntelligence #DrugDiscovery #Healthcare #SanDiego

Hearty congrats to Thomas Miller, Fred Manby, and team Iambic Therapeutics (formerly known as Entos), on securing their Series B round. We are thrilled to have partnered with them from 2020, when we led their seed round, and are delighted to have participated in this round alongside a group of stellar investors. 

We eagerly look forward to Iambic’s continued growth and success as they disrupt the therapeutics landscape with their unique generative AI-driven drug-discovery platform.

Jishnu B. I Nexus Venture Partners I #NexusVP

https://lnkd.in/ex3JkGZY

Iambic Therapeutics (previously #Entos) has successfully closed an oversubscribed $100 million Series B financing round, co-led by Ascenta Capital and Abingworth, with participation from new and existing investors including NVIDIA, #IlluminaVentures, and Sequoia Capital. 

These funds aim to bolster the development of their pioneering AI-driven drug discovery platform and advance several AI-identified therapeutic candidates. With a combined expertise in physics and AI, Iambic strives to revolutionize drug discovery. https://lnkd.in/eymxF8TF

Entos is now Iambic Therapeutics! We are excited to announce that Iambic has closed a $100 Million Series B to continue work on advancing AI-discovered therapeutics into clinical development as we enter a collaboration with NVIDIA.

This funding, co-led by Ascenta Capital and Abingworth, will support new AI platform innovations, advancement of multiple candidates into clinical development, and expansion of internal pipeline  across target classes and therapeutic areas.

Read the full press release at: https://lnkd.in/ex3JkGZY

#DrugDiscovery #ArtificialIntelligence #MachineLearning

Entos co-founder and CEO Thomas Miller joined the AI in Drug Discovery panel at #IDSD23, discussing clinical drug candidates created using the Entos AI-driven drug-discovery platform. A big thanks to Aiden Aceves, Ph.D. at Insight Partners for moderating and Connect for coordinating!

#DrugDiscovery #MachineLearning #AI

We are thrilled to see Entos included in Insider's list of most-promising healthcare start-ups of 2023 for accelerating the delivery of new drugs to clinic with our AI-driven high-throughput drug-discovery platform.

https://lnkd.in/e7MbKMb3

#artificialintelligence #healthcare #machinelearning #drugdiscovery

Join Entos CEO Thomas Miller at the The Camille and Henry Dreyfus Foundation/American Chemical Society Symposium on Machine Learning to learn about advances in AI-driven drug discovery!

Date: Tuesday, August 15, 3pm PT

https://lnkd.in/eZ4_C3Pg

#ACSFall2023 #machinelearning #drugdiscovery #artificialintelligence

HSTS

nginx

Cloudflare CDN

Cloudflare

Cloudflare Network Error Logging

Apple Mobile Web App Capable

Product Schema

Apple Mobile Web App Status Bar Style

Offer Schema

Google Conversion Linker

User Researcher

Frank Mojica

Maeve Wang

Founder & CEO

Fashion Companies With Fewer Than 50 Employees (Top 10K)

New York Female Founded Companies

New York Companies With More Than $1M in Revenue (Top 10K)

East Coast Companies With Less Than $10M in Revenue (Top 10K)

IAMBIC, acclaimed as one of TIME's Best Inventions of 2023, is on a mission to make shoes size-inclusive with AI-tailored footwear. IAMBIC's AI technology crafts footwear that addresses the unique fit issues ignored by traditional sizing systems, offering bespoke comfort to those marginalized by the one-size-fits-all approach. Holding 12 patent-pending inventions and supported by the National Science Foundation, the team is on the cusp of scaling bespoke shoes, which were once the preserve of the elite, and democratizing personalized luxury. With a world-class team of experts who hail from Nike, Ralph Lauren, Puma, Bain, L’Oreal, and Harvard, IAMBIC is committed to making inclusive sizing a reality in footwear. Discover more at: www.iambic.co.

news impact assignment basic	general	Oct 2, 2024 10:14 AM	8c9e204c
public peers	general	Oct 2, 2024 10:14 AM	86b14c95
news daily refresh	general	Oct 2, 2024 10:14 AM	7c014efb
news processing daily refresh	general	Oct 2, 2024 10:14 AM	249c745f
news impact assignment daily	general	Oct 2, 2024 10:14 AM	74b762b4
news processing basic	general	Oct 2, 2024 10:14 AM	92a77548
company summary	general	Oct 2, 2024 10:14 AM	1b5384fe
signals	general	Oct 2, 2024 10:14 AM	ba8453f1
crunchbase trigger	general	Nov 25, 2024 9:06 AM	d6f4dfd2
crunchbase profile	general	Nov 25, 2024 12:08 PM	ee7a75a7
li profile	general	Oct 27, 2023 9:04 AM	1c2a15e5
translate crunchbase fundingrounds	general	Nov 25, 2024 1:57 PM	b207b601
peers	general	Oct 2, 2024 10:14 AM	f3e362a6
news basic	general	Oct 2, 2024 10:14 AM	95784586
bundesanzeiger	filings	Oct 2, 2024 10:14 AM	989d612b
financials download nd	financials
private financials	financials

AI:IAMBIC

Iambic Therapeutics